# Nuclide record psmaddition (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/psmaddition/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "psmaddition", "NCT04720157" ;
  schema:name "PSMAddition"@en ;
  schema:description "PSMAddition moved the radioligand Pluvicto into the first treatment of metastatic hormone-sensitive prostate cancer, given alongside hormone therapy, and the FDA approved this use on 31 July 2026. It delayed progression on scans, but severe side effects were more common and whether it lengthens life is not yet known."@en ;
  schema:url <https://nuclide.cc/trials/psmaddition/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04720157>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy>, <https://www.annalsofoncology.org/article/S0923-7534(25)04871-9/fulltext> ;
  nuclide:status "positive" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mhspc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pluvicto/> .